Revolution Medicines, Inc., a Redwood City, Calif.-based company focused on frontier cancer targets and drug discovery inspired by nature’s lessons, raised $25m in a Series A extension financing.
The Column Group joined founding investor Third Rock Ventures.
The company intends to use the funds to advance its discovery programs toward clinical development. In conjunction with the funding, Larry Lasky, Ph.D., partner at The Column Group, joined Revolution Medicines’ Board of Directors.
Led by Mark A. Goldsmith, M.D., Ph.D., president and chief executive officer, Revolution Medicines discovers and develops new drugs directed toward frontier oncology targets for cancer patients. The company deploys an innovative toolkit including REVBLOCKS™, an integrated suite of modular synthesis methodologies applied to simple chemical building blocks, and the REVEAL™ computational platform, which uses evolution’s lessons to inform selection of chemical scaffolds and guide drug design for non-classical drug targets.